Biosimilars and Biologics

Among the most anticipated and discussed segments of the pharmaceutical market, biosimilars, are finally beginning to exert a greater impact on practice. To meet the growing need for information, ASHP has published Biosimilars and Biologics.

This authoritative, evidence-based resource provides an in-depth perspective on all areas related to these innovative drugs, including:


· Legislative/regulatory issues, including the biosimilars act and anticipated FDA guidelines

· The safety, efficacy, and interchangeability of biologics

· The science and analytical chemistry associated with the manufacture of biologics

· Needed pharmacovigilance and adverse effect reporting systems

· Formulary management